D. E. Shaw & Co. Inc. Decreases Stock Holdings in Glaukos Co. (NYSE:GKOS)

D. E. Shaw & Co. Inc. cut its stake in shares of Glaukos Co. (NYSE:GKOS - Free Report) by 99.5% in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 2,701 shares of the medical instruments supplier's stock after selling 495,859 shares during the quarter. D. E. Shaw & Co. Inc.'s holdings in Glaukos were worth $405,000 as of its most recent SEC filing.

Several other large investors also recently bought and sold shares of the business. Deutsche Bank AG increased its holdings in Glaukos by 49.6% in the 4th quarter. Deutsche Bank AG now owns 43,859 shares of the medical instruments supplier's stock worth $6,576,000 after buying an additional 14,540 shares in the last quarter. Divisadero Street Capital Management LP purchased a new position in Glaukos in the fourth quarter worth about $269,000. CoreCap Advisors LLC boosted its position in Glaukos by 36.4% in the fourth quarter. CoreCap Advisors LLC now owns 750 shares of the medical instruments supplier's stock worth $112,000 after purchasing an additional 200 shares during the last quarter. BOKF NA purchased a new position in Glaukos in the fourth quarter worth about $595,000. Finally, Brevan Howard Capital Management LP purchased a new position in shares of Glaukos during the 4th quarter valued at about $550,000. 99.04% of the stock is currently owned by institutional investors.

Insider Activity at Glaukos

In other Glaukos news, CFO Alex R. Thurman sold 1,520 shares of the company's stock in a transaction on Tuesday, March 25th. The stock was sold at an average price of $106.84, for a total value of $162,396.80. Following the completion of the sale, the chief financial officer now directly owns 53,431 shares in the company, valued at approximately $5,708,568.04. This represents a 2.77% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. 6.40% of the stock is owned by company insiders.

Analyst Upgrades and Downgrades

A number of research analysts have recently weighed in on the company. Piper Sandler lowered their price objective on Glaukos from $180.00 to $165.00 and set an "overweight" rating on the stock in a research report on Tuesday, April 15th. Stifel Nicolaus lowered their price objective on Glaukos from $140.00 to $115.00 and set a "buy" rating on the stock in a research report on Thursday, May 1st. Needham & Company LLC lowered their price objective on Glaukos from $176.00 to $115.00 and set a "buy" rating on the stock in a research report on Thursday, May 1st. Morgan Stanley lowered their price objective on Glaukos from $110.00 to $72.00 and set an "underweight" rating on the stock in a research report on Tuesday, May 6th. Finally, Truist Financial reaffirmed a "buy" rating and set a $135.00 price objective (down from $140.00) on shares of Glaukos in a research report on Thursday, May 1st. One equities research analyst has rated the stock with a sell rating, two have assigned a hold rating and ten have issued a buy rating to the company. According to MarketBeat, the company has a consensus rating of "Moderate Buy" and an average target price of $134.67.

Glaukos Price Performance

NYSE:GKOS traded down $0.54 during trading hours on Friday, reaching $94.33. The stock had a trading volume of 1,146,074 shares, compared to its average volume of 707,621. The company has a debt-to-equity ratio of 0.19, a quick ratio of 4.71 and a current ratio of 5.54. Glaukos Co. has a 52 week low of $77.10 and a 52 week high of $163.71. The company has a 50 day moving average price of $92.61 and a two-hundred day moving average price of $123.02. The stock has a market capitalization of $5.39 billion, a PE ratio of -32.87 and a beta of 0.83.

Glaukos (NYSE:GKOS - Get Free Report) last released its earnings results on Wednesday, April 30th. The medical instruments supplier reported ($0.22) earnings per share for the quarter, beating the consensus estimate of ($0.33) by $0.11. The firm had revenue of $106.66 million for the quarter, compared to the consensus estimate of $102.78 million. Glaukos had a negative return on equity of 16.53% and a negative net margin of 39.04%. The company's revenue for the quarter was up 24.6% compared to the same quarter last year. During the same quarter in the previous year, the company posted ($0.70) EPS. As a group, sell-side analysts anticipate that Glaukos Co. will post -1.08 earnings per share for the current fiscal year.

Glaukos Company Profile

Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent and iStent inject W micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-to-moderate open-angle glaucoma.